Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors. (October 2022) - Garralda, E.; Moreno, V.; Alonso, G.; Corral, E.; Hernandez-Guerrero, T.; Ramon, J.; Doger de Spéville, B.; Martinez, E.; Soucek, L.; Niewel, M.; Calvo, E.